Indianapolis, IN, United States of America

Manuel Debono



Average Co-Inventor Count = 1.8

ph-index = 15

Forward Citations = 490(Granted Patents)


Company Filing History:


Years Active: 1977-2010

Loading Chart...
Loading Chart...
Areas of Expertise:
Cyclic Peptide Antifungal Agents
Glycopeptide Antibiotics
Biotransformation
Phospholipase A2
Macrolide Antibiotics
Actinoplanes Missouriensis
N-Acyl Glycopeptide Derivatives
Antibiotic Factors
A-21978C Cyclic Peptides
Derivatives of A-30912
Pseudo-Aglycone
Antibiotic Aglycone
42 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Manuel Debono in Pharmaceutical Development

Introduction

Manuel Debono, an esteemed inventor based in Indianapolis, IN, has made significant strides in the field of pharmaceuticals. With a remarkable portfolio of 42 patents, he has contributed to advancements in antifungal and antibacterial agents, highlighting his role in the ever-evolving realm of medical innovation.

Latest Patents

Among his latest patents, Debono has developed cyclic peptide antifungal agents, introducing compounds of a specific formula that exhibit promising antifungal properties. Additionally, his work on anhydro- and isomer-A-21978C cyclic peptides has led to the identification of two new groups of these cyclic peptides, recognized for their antibacterial activity. These compounds serve as valuable intermediates in pharmaceutical formulations aimed at treating infections caused by susceptible Gram-positive bacteria. Notably, one of the breakthroughs includes a composition containing the new drug substance LY 146032 in a substantially pure form, showcasing his dedication to enhancing treatment options in modern medicine.

Career Highlights

Manuel Debono has built a prolific career at Eli Lilly and Company, a leading global pharmaceutical company. His innovations have not only secured numerous patents but have also positioned him as a key player in the development of therapies that address critical health challenges. His extensive research and dedication to pharmaceutical science underscore the impact of his work on patient care and treatment efficacy.

Collaborations

Throughout his career, Debono has collaborated with notable colleagues, including R. Michael Molloy and Frederick J. Burkhardt. These partnerships have undoubtedly enriched his research endeavors, fostering a collaborative environment that drives innovation and discovery in pharmaceutical development.

Conclusion

In summary, Manuel Debono's contributions to the pharmaceutical industry through his innovative patents and collaborations at Eli Lilly and Company exemplify the vital role of inventors in advancing medical science. His ongoing commitment to developing effective treatments underscores the importance of research and innovation in improving public health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…